



**ASX / Media Release**  
**5 May 2015**

## **Latest OncoSil Medical Investor Presentation**

SYDNEY, 5<sup>th</sup> May, 2015: OncoSil Medical Limited (ASX: OSL) (OncoSil Medical, the Company) is pleased to release its latest investor presentation, which will be delivered by CEO Daniel Kenny at Proactive Investors' investor forums this week, on the following dates;

**Melbourne:** Tuesday, 5 May 2015 at 12:00pm, at the CQ Melbourne Events Room 1, 113 Queen St, Melbourne.

**Sydney:** Wednesday, 6 May 2015 at 12:00pm, at the Radisson Blu Hotel, Cnr Pitt & O'Connell Sts, Sydney.

The presentation is also available at the OncoSil Medical Company website, at [www.oncosil.com.au](http://www.oncosil.com.au).

ENDS

Contact:

**Mr Daniel Kenny**  
**Chief Executive Officer and Managing Director**  
E: [daniel.kenny@oncosil.com.au](mailto:daniel.kenny@oncosil.com.au)  
T: +61 2 9223 3344

**James Moses**  
**Mandate Corporate**  
E: [james@mandatecorporate.com.au](mailto:james@mandatecorporate.com.au)  
M: +61 420 991 574  
T: +61 2 8211 0612

### **About OncoSil Medical Ltd**

OncoSil Medical Ltd (OncoSil Medical) is a clinical-stage Australian Lifesciences company focused on providing new technologies for safer medical radiation treatments. OncoSil Medical's lead product is OncoSil™ with the first target indication being pancreatic & hepatocellular cancer. OncoSil™ is a silicon and P32 (phosphorus) pure beta emitter with the potential to be used medically as a brachytherapy treatment. The OncoSil™ device delivers more concentrated and localised beta radiation compared to external beam radiation. OncoSil Medical has previously conducted four clinical trials with encouraging results on tolerability, safety and efficacy. There is also potential use for OncoSil™ in other solid tumours outside of pancreatic and hepatocellular cancer. FDA and CE Mark approval for pancreatic cancer is the core focus of OncoSil Medical.

### **Pancreatic Cancer**

Pancreatic cancer is typically diagnosed at a later stage, when there is a poor prognosis for long-term survival. The World Cancer Research Fund estimated that in 2012 338,000 people globally were diagnosed with pancreatic cancer including 43,140 Americans, 70,000 Europeans and 2,546 in Australia. The prognosis for patients diagnosed with pancreatic cancer, regardless of stage, is generally poor; the relative five-year survival rate for all stages combined is approximately 5%. The world-wide market for pancreatic drugs is projected by Global Industry Analysis to exceed US\$1.2bn in 2015.

### **Hepatocellular carcinoma liver cancer**

Hepatocellular carcinoma (HCC) is the 6<sup>th</sup> most common cancer in the world and afflicts almost a million patients annually. The poor prognosis makes HCC the third leading cause of cancer related mortality, responsible for approximately 600,000 deaths annually. HCC may be cured by surgery or transplantation. The vast majority of patients with HCC have disease which is too advanced for surgical intervention and as a consequence survival ranges from a few months to two or more years, depending on the liver function at diagnosis and the extent of tumour invasion. The value of the HCC market is expected to triple in size to \$1.4b by 2019.

ONCOSIL MEDICAL LIMITED ABN 89 113 824 141 ASX | OSL  
Suite 807, Level 8, 1 Alfred Street Sydney NSW 2000 AUSTRALIA  
TELEPHONE +61 2 9223 3344 FACSIMILE +61 2 9221 8535  
WEB [www.oncosil.com.au](http://www.oncosil.com.au)